Search
14/05/2024
The "Burden of Skin Diseases" Project: a population-based study on 44,689 participants from 27 European countries
Paul, C, Stratigos, AJ, Nijsten, T, Gisondi, P, Salavastru, C, Röecken, M, Taieb, C, Sampogna, F, Trakatelli, M, Puig, L, Richard, MA. The "Burden of Skin Diseases" Project: a population-based study on 44,689 participants from 27 European countries. MINERVA MEDICA. 2024; DOI:10.23736/S0026-4806.24.09262-0. PMID:38743041. IF:4.700(Q/D).
12/05/2024
Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis Group
Sahuquillo-Torralba, A, Mansilla-Polo, M, Pujol-Marco, C, Llamas-Velasco, M, Rull, EV, Villaverde, RR, Ferran, M, Pitarch, G, Lopez, A, Beltran, E, Urruticoechea-Arana, A, Riera-Monroig, J, Alsina, M, Vidal, D, Romero, IB, Notario, J, Carrascosa, JM, Gonzalez-Delgado, V, Mollet, J, Ribera, M, Gallardo, F. Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis Group. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2024; 63(12)DOI:10.1111/ijd.17238. PMID:38736107. IF:3.200(Q1/3D).
01/05/2024
Approach to the Epidemiology, Disease Management, and Current Challenges in the Management of Generalized Pustular Psoriasis Through a Survey Conducted Among Spanish Dermatologists
Vilarrasa, E, Rivera, R, Eiris, N, Carretero, G, de la Cueva, P, Carrascosa, JM. Approach to the Epidemiology, Disease Management, and Current Challenges in the Management of Generalized Pustular Psoriasis Through a Survey Conducted Among Spanish Dermatologists. Actas Dermo-Sifiliograficas. 2024; 115(5)DOI:10.1016/j.ad.2023.10.022. PMID:37925068. IF:(Q/D).
01/05/2024
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study
Pinter, A, Soliman, AM, Pivneva, I, Ghanbariamin, R, Yang, M, Truong, B, Puig, L, Lebwohl, M. Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study. Dermatology and Therapy. 2024; 14(5)DOI:10.1007/s13555-024-01164-6. PMID:38727996. IF:4.200(Q1/1D).
01/05/2024
Dose escalation of biologic treatment in patients with moderate-to-severe psoriasis in Japan
Tada, Y, Soliman, AM, Ishii, K, Sakuma, R, Pinter, A, Davis, M, Nunag, D, Buessing, M, Puig, L, Imafuku, S. Dose escalation of biologic treatment in patients with moderate-to-severe psoriasis in Japan. EXPERIMENTAL DERMATOLOGY. 2024; 33(5)DOI:10.1111/exd.15067. PMID:38757460. IF:3.100(Q2/3D).
01/05/2024
2-Hydroxyethyl methacrylate (2-HEMA) sensitization, a global epidemic at its peak in Spain?
Gatica-Ortega, ME, Pastor-Nieto, MA, Giménez-Arnau, AM, Mercader-García, P, Sanz-Sánchez, T, Carrascosa-Carrillo, JM, Córdoba-Guijarro, S, Sánchez-Pérez, J, Silvestre, JF, Frutos, FJOD, Tous-Romero, F, Fernández-Redondo, V, Serra-Baldrich, E, Ruíz-González, I, Pérez, RG, Miquel-Miquel, J, Guillén, PSP, Hervella-García, M, Heras-Mendaza, F, Gómez-de-la-Fuente, E, Zaragoza-Ninet, V, Gilo, AS, Rodríguez-Serna, M, Melé-Ninot, G, Descalzo, MA, de-Vega, M, García-Doval, I, Borrego, L. 2-Hydroxyethyl methacrylate (2-HEMA) sensitization, a global epidemic at its peak in Spain?. CONTACT DERMATITIS. 2024; 90(5)DOI:10.1111/cod.14520. PMID:38351475. IF:4.600(Q1/1D).